SCHEMBL14957276

SCHEMBL14957276

NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACE P12821 1/20 0.53
KDM4E B2RXH2 1/20 0.48
MAPT P10636 1/20 0.48
THRB P10828 1/20 0.48
ALOX15 P16050 1/20 0.48
NFKB1 P19838 1/20 0.48
PTGS2 P35354 1/20 0.48
THPO P40225 1/20 0.48
RECQL P46063 1/20 0.48
BLM P54132 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
ECE1 P42892 2/20 0.44
FOLH1 Q04609 1/20 0.42
PTGS1 P23219 2/20 0.42
SLC7A11 Q9UPY5 1/20 0.42
MME P08473 2/20 0.40
GSTK1 Q9Y2Q3 1/20 0.40
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23091324 1.00 ACE (0.53) ACEKDM4EMAPTTHRBALOX15
SCHEMBL27900740 1.00 ACE (0.53) ACEKDM4EMAPTTHRBALOX15
SCHEMBL30390254 0.97 ACE (0.50) ACEKDM4EMAPTTHRBALOX15
SCHEMBL16770226 0.97 ACE (0.50) ACEKDM4EMAPTTHRBALOX15
SCHEMBL10308197 0.97 ACE (0.50) ACEKDM4EMAPTTHRBALOX15
SCHEMBL30287995 0.95 ACE (0.49) ACEKDM4EMAPTTHRBALOX15
SCHEMBL30288037 0.95 ACE (0.49) ACEKDM4EMAPTTHRBALOX15
SCHEMBL16770230 0.92 ACE (0.46) ACEKDM4EMAPTTHRBALOX15
SCHEMBL30390004 0.92 ACE (0.46) ACEKDM4EMAPTTHRBALOX15
SCHEMBL30288001 0.92 ACE (0.46) ACEKDM4EMAPTTHRBALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083865-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF 3B PHARMACEUTICALS GMBH (DE) 2026-03-26 US claimed
US-12402621-B2 Method for increasing longevity and/or bud opening of cut flowers LETAVIS AB (SE) 2025-09-02 US claimed
EP-4583917-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF 3B Pharmaceuticals GmbH (DE) 2025-07-16 EP claimed
CN-119923279-A Prostate Specific Membrane Antigen (PSMA) ligands and uses thereof 3B制药有限公司 2025-05-02 CN claimed
CN-114591944-B High-sensitivity HPV virus detection kit 杭州康大晨星医学科技有限公司 2025-04-04 CN claimed
WO-2025068188-A1 STIMULATION OF PLANT GERMINATION LETAVIS AB (SE) 2025-04-03 WO claimed
WO-2024052431-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF 3B PHARMACEUTICALS GMBH (DE) 2024-03-14 WO claimed
CN-116769860-A Enzymatic hydrolysis of crayfish shells, oligopeptide family extracted from crayfish shells and application of crayfish shells 奇明达(北京)植物药物技术开发有限公司 2023-09-19 CN claimed
US-20230232749-A1 METHOD FOR VEGETATIVE PROPAGATION OF PLANTS LETAVIS AB (SE) 2023-07-27 US claimed
CN-115038711-B Synthesis method of atosiban 湖北健翔生物制药有限公司 2023-05-02 CN claimed
EP-4164386-A1 METHOD FOR VEGETATIVE PROPAGATION OF PLANTS Letavis AB (SE) 2023-04-19 EP claimed
US-20220408722-A1 METHOD FOR INCREASING LONGEVITY AND/OR BUD OPENING OF CUT FLOWERS LETAVIS AB (SE) 2022-12-29 US claimed
EP-4075971-A1 METHOD FOR INCREASING LONGEVITY AND/OR BUD OPENING OF CUT FLOWERS Letavis AB (SE) 2022-10-26 EP claimed
CN-115181157-A Method for preparing disulfide bond-containing polypeptide by solid-liquid phase combination 湖北健翔生物制药有限公司 2022-10-14 CN claimed
CN-114591944-A High-sensitivity HPV detection kit 杭州康大晨星医学科技有限公司 2022-06-07 CN claimed
US-20260083865-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF 3B PHARMACEUTICALS GMBH (DE) 2026-03-26 US disclosed
EP-4684030-A2 METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP Martin-Luther-Universität Halle-Wittenberg (DE) 2026-01-28 EP disclosed
EP-2610338-A1 METHOD FOR PRODUCING SUBSTANCE Kyowa Hakko Kirin Co., Ltd. (JP) 2013-07-03 EP disclosed
US-20130130317-A1 METHOD FOR PRODUCING SUBSTANCE KYOWA HAKKO KIRIN CO., LTD (JP) 2013-05-23 US disclosed
CN-102786687-A Polyasparaginyl-L-cysteine and polyasparaginyl-L-methionine with polymerization degree of 59, preparation method and application thereof SHANDONG BAYONN PHARMACEUTICAL TECHNOLOGY CO LTD 2012-11-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260083865-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF KLK3, FOLH1, PSMA1 ACE 1882/4885KDM4E 4115/4885MAPT 3498/4885
US-20220408722-A1 METHOD FOR INCREASING LONGEVITY AND/OR BUD OPENING OF CUT FLOWERS OXTR, CRH, CALCA ACE 2816/4885KDM4E 3118/4885MAPT 1961/4885
US-12402621-B2 Method for increasing longevity and/or bud opening of cut flowers OXTR, CRH, CALCA ACE 2816/4885KDM4E 3118/4885MAPT 1961/4885
US-20230232749-A1 METHOD FOR VEGETATIVE PROPAGATION OF PLANTS OXTR, AVPR1B, AVPR1A ACE 3450/4885KDM4E 3337/4885MAPT 220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.